Long-acting injectable form of HIV prevention outperforms daily pill in NIH study

(NIH/National Institute of Allergy and Infectious Diseases) A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by NIH. Findings from the Phase 2b/3 study, called HPTN 083, will be discussed during the 23rd Internatio...